Evidence map›Paper›PMID 41214337›Full record

ArticleActa pharmacologica Sinica2026

Resibufogenin ameliorates cerebral ischemia-reperfusion injury by modulating microglial redox homeostasis via Keap1-Nrf2-TFR1/ARE axis.

Yao Chen, Wen-Qing Shi, Pei Zhang, Ran Wang, Wen-Bo Ye, Guo-Qiang Lin, Shou-Jiao Peng, Jian-Ge Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta pharmacologica Sinica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. PANoptosis: potential new targets and therapeutic prospects in digestive diseases.Apoptosis : an international journal on programmed cell death · 2025
    Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yao ChenState Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Innovation Research Institute of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
Wen-Qing ShiState Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Innovation Research Institute of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
Pei ZhangState Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Innovation Research Institute of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
Ran WangState Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Innovation Research Institute of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
Wen-Bo YeState Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Innovation Research Institute of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
Guo-Qiang LinState Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Innovation Research Institute of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
Shou-Jiao PengState Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Innovation Research Institute of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China. pengshj08@163.com.
Jian-Ge ZhangState Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Innovation Research Institute of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China. jgzhang@shutcm.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cerebral ischemia-reperfusion injury (CIRI) represents a significant clinical challenge, with microglial homeostasis playing a critical role in its pathological progression. Venenum bufonis (VB) has been extensively utilized as a cardiotonic, analgesic, and antineoplastic agent in the clinical practice of traditional Chinese medicine. Resibufogenin (RBG) is a bufadienolide compound derived from VB that has a wide range of pharmacological activities, including antitumor, anti-inflammatory, and cardiovascular protective effects. In this study, we investigated the neuroprotective effects of RBG on the progression of CIRI and the underlying mechanisms. A CIRI model was established in rats by transient middle cerebral artery occlusion (tMCAO), after which the rats were administered RBG (2.6 or 4.0 mg·kg

Indexed as

Brain IschemiaBufanolidesMicrogliaNeuroprotective AgentsReperfusion InjuryAnimalsAntioxidant Response ElementsHomeostasisInfarction, Middle Cerebral ArteryKelch-Like ECH-Associated Protein 1MaleMiceNF-E2-Related Factor 2Oxidation-ReductionRatsRats, Sprague-DawleyBufanolidesbufogeninKEAP1 protein, ratKelch-Like ECH-Associated Protein 1Neuroprotective AgentsNfe2l2 protein, ratNF-E2-Related Factor 2Receptors, Transferriniron metabolismischemic strokemicrogliaNrf2oxidative stressresibufogenin

Identifiers

PMID41214337
PMCPMC12932844

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.